Home > Boards > US OTC > Miscellaneous > Therapeutic Solutions International, Inc. (TSOI)

TSOI NEWS History

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
centsability4me Member Profile
Member Level 
Followed By 33
Posts 3,280
Boards Moderated 3
Alias Born 06/17/13
160x600 placeholder
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/14/2019 3:35:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:05:22 PM
Therapeutics Solutions International Signs Agreement with Beijing Regenesis Biotechnology InvestorsHub NewsWire - 11/11/2019 9:00:00 AM
Therapeutics Solutions International Reports Augmentation of Rejuvenating Activity of Cord Blood Plasma by Pterostilbene InvestorsHub NewsWire - 11/4/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2019 12:59:28 PM
Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy InvestorsHub NewsWire - 9/9/2019 9:00:00 AM
Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer InvestorsHub NewsWire - 9/3/2019 9:00:00 AM
Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months InvestorsHub NewsWire - 8/29/2019 9:00:00 AM
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System InvestorsHub NewsWire - 8/26/2019 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2019 4:28:47 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/13/2019 1:46:36 PM
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients InvestorsHub NewsWire - 8/5/2019 9:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/30/2019 4:44:49 PM
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer InvestorsHub NewsWire - 7/29/2019 9:00:00 AM
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Ca... InvestorsHub NewsWire - 7/22/2019 9:00:00 AM
Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release InvestorsHub NewsWire - 7/15/2019 9:00:00 AM
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of InvestorsHub NewsWire - 7/11/2019 9:00:00 AM
Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product InvestorsHub NewsWire - 7/8/2019 9:00:00 AM
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of InvestorsHub NewsWire - 7/1/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 11:12:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/20/2019 11:18:31 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/14/2019 11:22:33 AM
Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratori... InvestorsHub NewsWire - 5/6/2019 9:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/15/2019 1:36:47 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 3/29/2019 11:33:18 AM
centsability4me Member Level  Thursday, 10/10/19 08:16:54 AM
Re: None
Post # of 12767 
TSOI NEWS History

NEWS 9/9/19
(re-posted for newbies)

Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System
from Cancer Chemotherapy
Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address
$3.9 Billion Chemotherapy Induced Neutropenia Market

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80689184/therapeutic-solutions-international-reports-nanost

OCEANSIDE, CA -- September 9, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today new data and the filing of a patent application covering the ability of NanoStilbene™ [1] and its active ingredient, pterostilbene, at accelerating recovery of blood cells after treatment with chemotherapy.

Neutropenia is an abnormally low number of neutrophils (a type of white blood cell) in the blood. Neutropenia, if severe, significantly increases the risk of life-threatening infection. Neutropenia is often a side effect of the treatment of cancer with chemotherapy or radiation therapy.

In animals treated with the chemotherapeutic agent 5-fluorouracil, recovery of white blood cells occurred significantly faster in animals that also received NanoStilbene™ as compared to animals that received a placebo. The results were replicated with other types of chemotherapy including high dose cyclophosphamide and busulfan.

"We have previously reported that NanoStilbene™ can synergize with low dose cyclophosphamide at increasing immune response and killing of cancer [2]" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "This new data supports the possibility of using NanoStilbene™ in many cancer patients who are taking chemotherapy, in order to protect the patients from the side effects of chemotherapy. In many cases, patients receiving chemotherapy have reduced white blood cells, which causes various types of infectious disease."

Currently, drugs such as Neulasta™ and Neupogen™ are used for increasing white blood cells in cancer patients taking chemotherapy. Unfortunately, these drugs cannot be taken prophylactically, and are highly expensive. According to Fierce Pharma, Neulasta™ had sales of $3.8 billion in 2018 [3]. More importantly, NanoStilbene possesses direct cancer-inhibitory properties, meaning that potentially it not only prevents chemotherapy-associated side effects but also increases the activity of the chemotherapy to kill cancer.

"I am impressed by the wide spectrum activity of the NanoStilbene™ product. It is very rare to find a therapy that concurrently suppresses the growth of cancer, stimulates the immune system, and protects the bone marrow from chemotherapy-induced toxicity" said Dr. Feng Lin, Chief Scientific Officer of the Company. "Since NanoStilbene™ is already on the market as a nutraceutical, I anticipate it will rapidly be utilized by informed patients who are suffering from cancer."

NanoStilbene is a nanoemulsion of nanoparticle pterostilbene in the range of 75-100nm at a concentration of 200mg per milliliter. Nanoparticle therapeutics is an emerging treatment modality for cancer and other inflammatory disorders. The National Cancer Institute has recognized nanotechnology as an emerging field with the potential to revolutionize modern medicine for the detection, treatment, and prevention of cancer.

"This Company was founded not only to advance great science but more importantly, to help patients for which limited options exist. The development of NanoStilbene™, we believe, offers the potential of a new generation of non-toxic compounds that concurrently stimulate the immune system while suppressing cancer at the same time" said Timothy Dixon, President, and CEO of the Company.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.

[1] https://mynanostilbene.com/?page_id=159
[2] https://www.globenewswire.com/news-release/2019/07/29/1892915/0/en/NanoStilbene-Nutraceutical-Shown-to-Increase-Ability-of-Cyclophosphamide-Chemotherapy-to-Suppress-Cancer.html
[3] https://www.fiercepharma.com/special-report/9-neulasta

NEWS 9/3/19

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer
Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA


http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80650612/feng-lin-md-ph-d-joins-therapeutic-solutions-i

NEWS 8/29/19
Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80626982/therapeutic-solutions-international-inc-reports

NEWS 8/26/19
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients
Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80602113/therapeutic-solutions-international-announces-posi

NEWS 8/5/19

Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
Company Plans to Advance its Phase I Cancer Immunotherapy StemVacs™ to US Patients

https://www.globenewswire.com/news-release/2019/08/05/1896899/0/en/Therapeutic-Solutions-International-Collaborates-with-Right-to-Try-Foundation-on-Novel-Means-of-Protecting-Patients-While-Hyper-accelerating-Drug-Development.html

NEWS 7/29/19
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer
Recent Data Supports Investigation of Commercially Available Product
as an Adjuvant to Chemotherapy for Cancer

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80417735/nanostilbene-8482-nutraceutical-shown-to-increas

NEWS 7/22/19
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer
New Data Supports Development of Patented Formulation of Blueberry Extract Pterostilbene as an Adjuvant to Immuno-Oncology Treatments

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80371866/therapeutic-solutions-international-reports-its-na

NEWS 7/15/19

Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80328380/therapeutic-solutions-international-adds-nano-cann

NEWS 7/11/19
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA
Company Reports Synergistic Activation of Anti-Cancer Protein NRF2 By Proprietary Combination Approach

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80311774/therapeutic-solutions-international-develops-adjuv

NEWS 7/8/19
Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80285424/therapeutic-solutions-international-develops-gluco

NEWS 7/1/19
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of Military and Sports Brain Injuries
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80242706/therapeutic-solutions-international-obtains-exclus

NEWS 5/6/19
Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratories, LLC.
NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79840011/therapeutic-solutions-international-awards-distrib

NEWS 2/19/19
Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation
NanoStilbene Shown to Reduce Tumor Necrosis Factor-a (TNF-a ) in Cancer Patients

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79295986/therapeutic-solutions-international-continues-to-r


TSOI News History 5/1/18 - 1/22/19


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146277441

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist